Rochester, NY (PRWEB) January 12, 2014
The editors of Science magazine picked cancer immunotherapy as 2013’s major medical breakthrough achievement. Cancer immunotherapy is the use of the immune system to fight cancer. This is done by stimulating the patient's immune system to attack cancer cells. According to an article on NewsObserver.com, “Scientists have thought for decades that harnessing the immune system to battle tumors should be possible, but it has been incredibly difficult to make it work.” The article was published on January 5, 2014 (2).
“So far, this strategy of harnessing the immune system to attack tumours works only for some cancers and a few patients, so it's important not to overstate the immediate benefits. But many cancer specialists are convinced that they are seeing the birth of an important new paradigm for cancer treatment,” said Tim Appenzeller, chief news editor of Science magazine (1).
Cancer researchers say that they “have turned a corner because two different techniques are helping a subset of patients. One involves antibodies that release a brake on (or stimulate) T cells (a type of white blood cell), giving them the power to tackle tumors. Another involves genetically modifying an individual's T cells outside the body so that they are better able to target cancer, and then re-infusing them so they can do just that. (2).”
Normal cells are programmed to divide and replicate at a certain rate. Cancer cells replicate unchecked, which causes the growth of a tumor. Now, think of the immune system’s T-Cells as guards. They seek out and destroy malfunctioning cells, including cancer cells. In essence, cancer immunotherapy is either adding T-Cells (adding more guards) or teaching them to be more aggressive.
According to the Theory of Microcompetition with Foreign DNA, as detailed by Dr. Hanan Polansky on the CBCD website (3), latent viruses are the cause of most major diseases, including cancer. Latent viruses microcompete for scarce genetic resources in the cells they infect. This causes the cell to “go crazy,” or malfunction.
As long as the immune system is efficient, the T-Cells will find all the malfunctioning cells, and destroy them. Otherwise, some cells will survive and become tumors.
The CBCD sees immunotherapy as an attempt to compensate for a weak immune system. That is, to entice the weak immune system to find malfunctioning cells, specifically those with a high concentration of latent viruses.
However, by eradicating latent viral infections, and therefore avoiding Microcompetition from the start, patients will not develop cancer and will not need cancer therapies.
The Center recommends that health professionals turn to Dr. Polansky’s book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease” for a better understanding of the risks posed by latent viruses, and how helping the immune system to eradicate them may improve cancer patient outcomes.
To learn more about Dr. Hanan Polansky’s research and the Theory of Microcompetition with Foreign DNA, visit: http://www.cbcd.net.
(1) Science journal’s top 10 breakthroughs, 2013. Published on December 26, 2013.
(2) Science magazine picks top breakthroughs of 2013. Published on January 5, 2014.
(3) CBCD - Foreign DNA Fragments Cause Most Major Diseases.
The CBCD is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.
The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.
Read the full story at http://www.prweb.com/releases/2014/01/prweb11475475.htm.
Copyright©2012 Vocus, Inc.
All rights reserved